Skip to main content
SpringerLink
Log in

Beyond BCG: Taxanes

  • Chapter
  • First Online:
Bladder Cancer

Part of the book series: Current Clinical Urology ((CCU))

Abstract

Many patients undergoing intravesical therapy for superficial bladder cancer will fail initial treatment; therefore additional bladder-sparing options are needed for these patients. The taxanes are potentially ideal agents for intravesical therapy as they have demonstrated efficacy as systemic agents and have little systemic absorption due to a large molecular weight. Early clinical research indicates minimal toxicities associated with the use of taxanes as an intravesical treatment. These agents may yet play an important role in the intravesical treatment of bladder cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kim SC, Steinberg GD. Medical management of patients with refractory carcinoma in situ of the bladder. Drugs Aging 18:335–344, 2001.

    Article  CAS  PubMed  Google Scholar 

  2. Malmström P-U, Wijkström, Lundholm C, et al. 5-year followup of a randomized prospective study comparing mitymycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma. J Urol 161:1124–1127, 1999.

    Article  PubMed  Google Scholar 

  3. Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. Valrubicin Study Group. J Urol 163:761–767, 2000.

    Article  CAS  PubMed  Google Scholar 

  4. Palapattu GS, Haisfield-Wolfe ME, Walker JM, et al. Assessment of perioperative psychological distress in patients undergoing radical cystectomy for bladder cancer. J Urol 172:1814–1817, 2004.

    Article  PubMed  Google Scholar 

  5. Parkinson JP, Konety BR: Health related quality of life assessments for patients with bladder cancer. J Urol 172:2130–2136, 2004.

    Article  PubMed  Google Scholar 

  6. Babaian RJ, Smith DB. Effect of ileal conduit on patients' activities following radical cystectomy. Urology 37:33–35, 1991.

    Article  CAS  PubMed  Google Scholar 

  7. Crawford ED. Intravesical therapy for superficial cancer: need for more options. J Clin Oncol 20:3185–3186, 2002.

    PubMed  Google Scholar 

  8. Bissey MC, Nohynek G, Sanderink GJ, et al. Docetaxel (Taxotere(R)): a review of preclinical and clinical experience. Part I: preclinical experience. AntiCancer Drugs 6:339–355; 363–8, 1995.

    Article  Google Scholar 

  9. Hennequin C, Fiocanti N, Favaudon V. S-phase specificity of cell killing of docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer 71:1194–1198, 1995.

    CAS  PubMed  Google Scholar 

  10. Rangel C, Niell H, Miller A, et al. Taxol and taxotere in bladder cancer: in vitro activity and urine stability. Cancer Chemother Pharmacol 33:460–464, 1994.

    Article  CAS  PubMed  Google Scholar 

  11. Roth BJ, Dreicer R, Einhorn LH et al. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12: 2264–70, 1994.

    CAS  PubMed  Google Scholar 

  12. deWit R, Kruit WH, Stoter G, et al. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer 78:1342–1345, 1998.

    CAS  Google Scholar 

  13. Gitlitz BJ, Baker C, Chapman Y, et al. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer 98:1863–1869, 2003.

    Article  CAS  PubMed  Google Scholar 

  14. Pectasides D, Glotsos J, Bountouroglou N, et al. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Ann Oncol 13:243–250, 2002.

    Article  CAS  PubMed  Google Scholar 

  15. Garcia del Muro X, Marcuello E, Guma J, et al. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer 86:326–330, 2002.

    Article  CAS  PubMed  Google Scholar 

  16. Pectasides D, Visvikis A, Aspropotamitis A, et al. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial. Eur J Cancer 36:74–79, 2000.

    Article  CAS  PubMed  Google Scholar 

  17. Uchio EM, Linehan WM, Figg WD, et al. A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder. J Urol 169:357–360, 2003.

    Article  CAS  PubMed  Google Scholar 

  18. Messing E, Catalona. Urothelial tumors of the urinary tract. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ (eds.) Campbell's Urology, 7rd Ed., vol. 3. PhiladelphiaP: WB Saunders Company, 2327–2410, 1998.

    Google Scholar 

  19. Song D, Wientjes MG, Au JL. Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol 40:285–292, 1997.

    Article  CAS  PubMed  Google Scholar 

  20. McKiernan JM, Masson P, Murphy AM, Goetzl M, Olsson CA, Petrylak DP, Desai M, Benson MC. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 24(19):3075–80, 2006.

    Article  CAS  PubMed  Google Scholar 

  21. Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H and Mason MD. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU International 93:485–90, 2004.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Columbia University Medical Center, New York, NY, USA

    James M. McKiernan & Phillip M. Pierorazio

Authors
  1. James M. McKiernan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Phillip M. Pierorazio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James M. McKiernan .

Editor information

Editors and Affiliations

  1. Dept. Urology, University of Michigan Health System, E. Medical Center Dr. 1500 , Ann Arbor, 48109-0252, U.S.A.

    Cheryl T. Lee

  2. Dept. Urology, University of Michigan Health System, E. Medical Center Dr. 1500 , Ann Arbor, 48109-0252, U.S.A.

    David P. Wood

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

McKiernan, J.M., Pierorazio, P.M. (2009). Beyond BCG: Taxanes. In: Lee, C., Wood, D. (eds) Bladder Cancer. Current Clinical Urology. Humana Press. https://doi.org/10.1007/978-1-59745-417-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-417-9_13

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-988-8

  • Online ISBN: 978-1-59745-417-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation